A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy
Latest Information Update: 02 Jul 2026
At a glance
- Drugs BMN 351 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 25 Jun 2026 Planned primary completion date changed from 30 Sep 2026 to 14 Apr 2027.
- 25 Jun 2026 Status changed from recruiting to active, no longer recruiting.
- 13 May 2026 According to Clinical Trials Information System this study is completed in Spain and Netherlands.